齐拉西酮与利培酮治疗女性精神分裂症对照研究

目的探讨齐拉西酮与利培酮治疗女性精神分裂症患者的临床疗效及安全性。方法将64例精神分裂症患者随机分为两组，每组32例，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察8周。于治疗前及治疗第2周、4周、8周末采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降（P〈o．01），同期两组问比较均无显著性差异（P〉0．05）。治疗8周末，研究组显效率71．88％，有效率为84．38％；对照组分别为84．38％，93．75％。两组疗效无显著性差异（P〉0．05）。两组不良反应均较轻微，研究组主要表现为头晕和锥体外系反应，对照组主要表现为体质量增加。结论齐拉西酮与利培酮治疗女性精神分裂症疗效均显著且相当，安全性高，依从性好。

A control study of ziprasidone vs risperidone in the treatment of female schizophrenia

Objective To assess the clinical efficary and satety of zipraszctone vs risperidone in the treatment of female schizophrenia. Methods Fifty six schizophrenics were randomly assigned to two groups of 28 patients each, research group took orally ziprasidone and control group did risperidone for 8 weeks. Clinical efficacies were assessed with Positive and Negative Syndrome Scale（PANSS） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the end of the 2nd, 4th, 6th anf 8th week. Results Since the end of the 2nd week, the total and each factor score of the PANSS of both groups lowered more significantly compared with pretreatment（P〈0.01）, there were no significant differences in synchronization group comparison（P〉0. 05）. At the end of the 8th week, obvoius effective and effective rates were 75.00% and 89.29% in the research and 71.4% and 89. 29% in the control group respectively,which showed no significant differences（P〉0.05）. Research group had lower incidence and mild adverse reactions, the incidences of acute dysmyotonia, akathisia, weight gain, menstrual disorder and ecg abnormal as well as the TESS score were significantly lower compared with the control group（P〈0.05 or 0.01）. Conclusion Both ziprasidone and risperidone have equivalent evident effects in female schizophrenia, but the former has higher safety and better compliance and is a safe and effective antipsychotic drug.